Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM.

J Clin Oncol. 2018 May 10;36(14):1428-1439. doi: 10.1200/JCO.2017.76.0793. Epub 2018 Mar 27.

PMID:
29584546
2.

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, Sasse S, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman J, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Ansell S, Kato K, Farsaci B, Sumbul A, Armand P, Neuberg DS, Pinkus GS, Ligon AH, Rodig SJ, Shipp MA.

J Clin Oncol. 2018 Apr 1;36(10):942-950. doi: 10.1200/JCO.2017.77.3994. Epub 2018 Feb 2.

PMID:
29394125
3.

Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy.

Farsaci B, Donahue RN, Grenga I, Lepone LM, Kim PS, Dempsey B, Siebert JC, Ibrahim NK, Madan RA, Heery CR, Gulley JL, Schlom J.

Cancer Immunol Res. 2016 Sep 2;4(9):755-65. doi: 10.1158/2326-6066.CIR-16-0037. Epub 2016 Aug 2.

4.

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MG, Ligon AH, Engert A.

Lancet Oncol. 2016 Sep;17(9):1283-94. doi: 10.1016/S1470-2045(16)30167-X. Epub 2016 Jul 20.

5.

137O: Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profling analyses.

Lena H, Rizvi NA, Wolf J, Cappuzzo F, Zalcman G, Baas P, Mazieres J, Farsaci B, Blackwood-Chirchir MA, Ramalingam S.

J Thorac Oncol. 2016 Apr;11(4 Suppl):S115-6. doi: 10.1016/S1556-0864(16)30247-7. Epub 2016 Apr 15. No abstract available.

6.

Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack.

Grenga I, Kwilas AR, Donahue RN, Farsaci B, Hodge JW.

J Immunother Cancer. 2015 Nov 17;3:52. doi: 10.1186/s40425-015-0096-7. eCollection 2015.

7.

Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.

Heery CR, Ibrahim NK, Arlen PM, Mohebtash M, Murray JL, Koenig K, Madan RA, McMahon S, Marté JL, Steinberg SM, Donahue RN, Grenga I, Jochems C, Farsaci B, Folio LR, Schlom J, Gulley JL.

JAMA Oncol. 2015 Nov;1(8):1087-95. doi: 10.1001/jamaoncol.2015.2736. Erratum in: JAMA Oncol. 2015 Nov;1(8):1171-2.

PMID:
26291768
8.

Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.

Farsaci B, Donahue RN, Coplin MA, Grenga I, Lepone LM, Molinolo AA, Hodge JW.

Cancer Immunol Res. 2014 Nov;2(11):1090-102. doi: 10.1158/2326-6066.CIR-14-0076. Epub 2014 Aug 4.

9.

Therapeutic cancer vaccines.

Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Farsaci B, Madan RA, Heery CR, Gulley JL.

Adv Cancer Res. 2014;121:67-124. doi: 10.1016/B978-0-12-800249-0.00002-0. Review.

PMID:
24889529
10.

Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.

Gulley JL, Madan RA, Tsang KY, Jochems C, Marté JL, Farsaci B, Tucker JA, Hodge JW, Liewehr DJ, Steinberg SM, Heery CR, Schlom J.

Cancer Immunol Res. 2014 Feb;2(2):133-41. doi: 10.1158/2326-6066.CIR-13-0108. Epub 2013 Nov 4.

11.

Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy.

Kim PS, Jochems C, Grenga I, Donahue RN, Tsang KY, Gulley JL, Schlom J, Farsaci B.

J Immunol. 2014 Mar 15;192(6):2622-33. doi: 10.4049/jimmunol.1301369. Epub 2014 Feb 10.

12.

Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets.

Farsaci B, Jochems C, Grenga I, Donahue RN, Tucker JA, Pinto PA, Merino MJ, Heery CR, Madan RA, Gulley JL, Schlom J.

Int J Cancer. 2014 Aug 15;135(4):862-70. doi: 10.1002/ijc.28743. Epub 2014 Feb 22.

13.

Effects of conventional therapeutic interventions on the number and function of regulatory T cells.

Roselli M, Cereda V, di Bari MG, Formica V, Spila A, Jochems C, Farsaci B, Donahue R, Gulley JL, Schlom J, Guadagni F.

Oncoimmunology. 2013 Oct 1;2(10):e27025.

14.

Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.

Ardiani A, Farsaci B, Rogers CJ, Protter A, Guo Z, King TH, Apelian D, Hodge JW.

Clin Cancer Res. 2013 Nov 15;19(22):6205-18. doi: 10.1158/1078-0432.CCR-13-1026. Epub 2013 Sep 18.

15.

Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.

Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR.

Int J Cancer. 2013 Aug 1;133(3):624-36. doi: 10.1002/ijc.28070. Epub 2013 Mar 16.

16.

The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

Hodge JW, Ardiani A, Farsaci B, Kwilas AR, Gameiro SR.

Semin Oncol. 2012 Jun;39(3):323-39. doi: 10.1053/j.seminoncol.2012.02.006. Review.

17.

Distinct effects of saracatinib on memory CD8+ T cell differentiation.

Takai S, Sabzevari H, Farsaci B, Schlom J, Greiner JW.

J Immunol. 2012 May 1;188(9):4323-33. doi: 10.4049/jimmunol.1101439. Epub 2012 Mar 26.

18.

Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.

Farsaci B, Higgins JP, Hodge JW.

Int J Cancer. 2012 Apr 15;130(8):1948-59. doi: 10.1002/ijc.26219. Epub 2011 Aug 8.

19.

Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine.

Farsaci B, Sabzevari H, Higgins JP, Di Bari MG, Takai S, Schlom J, Hodge JW.

Int J Cancer. 2010 Oct 1;127(7):1603-13. doi: 10.1002/ijc.25177.

20.

TGF-beta modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression.

di Bari MG, Lutsiak ME, Takai S, Mostböck S, Farsaci B, Semnani RT, Wakefield LM, Schlom J, Sabzevari H.

Cancer Immunol Immunother. 2009 Nov;58(11):1809-18. doi: 10.1007/s00262-009-0692-9. Epub 2009 Mar 25.

21.

Adverse events after infusions of cryopreserved hematopoietic stem cells depend on non-mononuclear cells in the infused suspension and patient age.

Milone G, Mercurio S, Strano A, Leotta S, Pinto V, Battiato K, Coppoletta S, Murgano P, Farsaci B, Privitera A, Giustolisi R.

Cytotherapy. 2007;9(4):348-55.

PMID:
17573610
22.

CD34+ selected haematopoietic stem cell (HSC) not preceded by any immunosuppressive therapy as effective treatment for graft failure.

Milone G, Tornello A, Leotta S, Poidomani M, Mercurio S, Farsaci B, Consoli C, Murgano P, Giustolisi R.

Bone Marrow Transplant. 2005 Mar;35(5):521-2; author reply 522. No abstract available.

PMID:
15665846

Supplemental Content

Loading ...
Support Center